You are here

Article Text

Article menu

other Versions

Download PDFPDF
PostScript
Correspondence
Safety of long-acting β-agonists in asthma
  1. Gustavo J Rodrigo1,
  2. Jose A Castro-Rodriguez2
  1. 1Emergency Department, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay
  2. 2School of Medicine, Pontificia Universidad Catolica de Chile, Las Condes, Santiago, Chile
  1. Correspondence to Dr Gustavo J Rodrigo, Emergency Department, Hospital Central de las Fuerzas Armadas, Uruguay, Av. 8 de Octubre 3020, Montevideo 11300, Uruguay; gurodrig{at}adinet.com.uy

https://doi.org/10.1136/thoraxjnl-2012-202014

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The study by Wolfe et al1 certainly does not support our claim that serious asthma exacerbations are more frequent in patients receiving formoterol 24 μg twice daily than in those receiving …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.